Source 1review2024Cell Reports Medicine
Toolkit/antisense oligonucleotides
antisense oligonucleotides
Also known as: ASOs
Taxonomy: Mechanism Branch / Component. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Gene therapies such as antisense oligonucleotides (ASOs) ... have played crucial roles in discovering and validating new pain targets.
Usefulness & Problems
Why this is useful
ASOs are presented as a major class of RNA therapeutics within RNA-targeted therapy. The review places them among strategies used for gene silencing and other RNA-directed applications.; gene silencing; RNA-targeted therapy; Antisense oligonucleotides are presented as a therapeutic component class for modulating RNA targets in TNBC-related ncRNA therapy.; therapeutic modulation of ncRNA-related targets in TNBC; ASOs are presented as a gene-therapy strategy used to modulate pain-relevant molecular targets. The review frames them as tools for discovering and validating new pain targets.; gene-based modulation of pain-relevant targets; target discovery and validation in chronic pain
Source:
ASOs are presented as a major class of RNA therapeutics within RNA-targeted therapy. The review places them among strategies used for gene silencing and other RNA-directed applications.
Source:
gene silencing
Source:
RNA-targeted therapy
Source:
Antisense oligonucleotides are presented as a therapeutic component class for modulating RNA targets in TNBC-related ncRNA therapy.
Source:
therapeutic modulation of ncRNA-related targets in TNBC
Source:
ASOs are presented as a gene-therapy strategy used to modulate pain-relevant molecular targets. The review frames them as tools for discovering and validating new pain targets.
Source:
gene-based modulation of pain-relevant targets
Source:
target discovery and validation in chronic pain
Problem solved
ASOs help address disease by targeting RNA rather than proteins, expanding therapeutic intervention at the RNA-regulatory level.; providing an RNA-based therapeutic modality for disease treatment; They offer a direct way to intervene at the RNA level rather than through protein-targeted drugs.; providing a direct oligonucleotide-based route to modulate RNA targets; They help address molecular targets that remain difficult to manipulate with traditional methods in chronic pain research and therapy.; helps address pain targets that are difficult to target with traditional methods
Source:
ASOs help address disease by targeting RNA rather than proteins, expanding therapeutic intervention at the RNA-regulatory level.
Source:
providing an RNA-based therapeutic modality for disease treatment
Source:
They offer a direct way to intervene at the RNA level rather than through protein-targeted drugs.
Source:
providing a direct oligonucleotide-based route to modulate RNA targets
Source:
They help address molecular targets that remain difficult to manipulate with traditional methods in chronic pain research and therapy.
Source:
helps address pain targets that are difficult to target with traditional methods
Problem links
helps address pain targets that are difficult to target with traditional methods
LiteratureThey help address molecular targets that remain difficult to manipulate with traditional methods in chronic pain research and therapy.
Source:
They help address molecular targets that remain difficult to manipulate with traditional methods in chronic pain research and therapy.
providing a direct oligonucleotide-based route to modulate RNA targets
LiteratureThey offer a direct way to intervene at the RNA level rather than through protein-targeted drugs.
Source:
They offer a direct way to intervene at the RNA level rather than through protein-targeted drugs.
providing an RNA-based therapeutic modality for disease treatment
LiteratureASOs help address disease by targeting RNA rather than proteins, expanding therapeutic intervention at the RNA-regulatory level.
Source:
ASOs help address disease by targeting RNA rather than proteins, expanding therapeutic intervention at the RNA-regulatory level.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Component: A low-level RNA part used inside a larger architecture that realizes a mechanism.
Mechanisms
No mechanism tags yet.
Techniques
No technique tags yet.
Target processes
editingrecombinationInput: Light
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenimplementation constraint: spectral hardware requirementoperating role: sensor
The abstract links progress in RNA therapeutics broadly to advances in delivery technologies, chemical modification, and related enabling methods. It does not specify a single ASO delivery platform in the abstract.; requires sufficient in vivo stability; requires effective delivery; They require target-specific oligonucleotide design and, in practice, a delivery context, though the supplied payload does not detail exact chemistries or carriers.; requires sequence-specific oligonucleotide design against the intended RNA target; likely depends on a delivery strategy, but the anchor review text was not provided to specify this; Use requires a delivery approach to the relevant pain-associated cells or tissues. The abstract does not specify chemistry, route, or formulation details.; requires delivery to target cells relevant to pain
The abstract states that translational barriers remain, including in vivo stability, delivery efficiency, and immune activation.; broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; The current evidence does not identify which ASO formats, targets, or delivery systems are most successful in the reviewed studies.; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review; The abstract does not show that ASOs broadly solve clinical pain treatment on their own, and it notes that pain-focused gene therapy trials remain uncommon.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2review2026PMC
Ranked Claims
Exosomes, nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides are presented in the supplied summary as recurring or relevant component classes for TNBC ncRNA therapeutics.
Gene-therapy modalities including ASOs, RNAi, CRISPR, and virus-based delivery systems have played crucial roles in discovering and validating new pain targets.
The review covers ASOs, siRNAs, optogenetics, chemogenetics, CRISPR, and their delivery methods targeting primary sensory neurons and non-neuronal cells including glia and chondrocytes.
Although gene therapy-based clinical trials have increased, trials focused on pain as the primary outcome remain uncommon.
Approval Evidence
3 sources9 linked approval claimsfirst-pass slug antisense-oligonucleotides
The supplied web research summary lists antisense oligonucleotides as an explicit therapeutic component class relevant to the anchor review topic.
Source:
Advances in high-throughput sequencing, structural biology, and delivery technologies have accelerated the development of diverse RNA therapeutics, including antisense oligonucleotides (ASOs).
Source:
Gene therapies such as antisense oligonucleotides (ASOs) ... have played crucial roles in discovering and validating new pain targets.
Source:
application scopesupports
RNA-based strategies are applied to gene silencing, editing, protein replacement, immune activation, and targeted drug delivery.
Source:
delivery modality recurrencesupports
Exosomes, nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides are presented in the supplied summary as recurring or relevant component classes for TNBC ncRNA therapeutics.
Source:
disease emphasissupports
ASOs and siRNAs receive special emphasis for neurological, metabolic, and infectious diseases.
Source:
field shiftsupports
RNA-targeted therapy is shifting molecular medicine from a protein-centric view toward an RNA-regulatory network paradigm.
Source:
modality coveragesupports
Diverse RNA therapeutics include ASOs, siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
translational barriersupports
Common challenges for RNA therapeutics include in vivo stability, delivery efficiency, and immune activation.
Source:
review summarysupports
Gene-therapy modalities including ASOs, RNAi, CRISPR, and virus-based delivery systems have played crucial roles in discovering and validating new pain targets.
Source:
scope of reviewsupports
The review covers ASOs, siRNAs, optogenetics, chemogenetics, CRISPR, and their delivery methods targeting primary sensory neurons and non-neuronal cells including glia and chondrocytes.
Source:
translational landscapesupports
Although gene therapy-based clinical trials have increased, trials focused on pain as the primary outcome remain uncommon.
Source:
Comparisons
Source-stated alternatives
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; The supplied summary points to exosomes, nanoparticles, liposomes, and aptamer-siRNA systems as adjacent approaches.; The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
The supplied summary points to exosomes, nanoparticles, liposomes, and aptamer-siRNA systems as adjacent approaches.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Source-backed strengths
highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary; explicitly described as playing a crucial role in discovering and validating new pain targets
Source:
highlighted as a major RNA therapeutic modality
Source:
given special emphasis for neurological, metabolic, and infectious diseases
Source:
explicitly named as a therapeutic component class in the supplied summary
Source:
explicitly described as playing a crucial role in discovering and validating new pain targets
Compared with antisense oligonucleotide
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with anti-sense oligonucleotides
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with aptazyme-embedded guide RNAs
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Compared with chemogenetics
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with CRISPR/Cas9
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with CRISPR/Cas9 system
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with Exosomes
The supplied summary points to exosomes, nanoparticles, liposomes, and aptamer-siRNA systems as adjacent approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The supplied summary points to exosomes, nanoparticles, liposomes, and aptamer-siRNA systems as adjacent approaches.
Compared with guide RNA
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Compared with microRNA
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Compared with optogenetic functional interrogation
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with optogenetic membrane potential perturbation
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with sgRNA
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Compared with small interfering RNA
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; The supplied summary points to exosomes, nanoparticles, liposomes, and aptamer-siRNA systems as adjacent approaches.; The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
The supplied summary points to exosomes, nanoparticles, liposomes, and aptamer-siRNA systems as adjacent approaches.
Source:
The review contrasts ASOs with RNAi, siRNAs, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with synthetically engineered guide RNA
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; explicitly named as a therapeutic component class in the supplied summary.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; the provided payload does not specify exact target classes, chemistries, or delivery dependencies from the anchor review.
Source:
The review compares ASOs with other RNA modalities including siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Ranked Citations
- 1.
- 2.